Last updated: February 13, 2026
What is the current market status of NDC 00143-9803?
NDC 00143-9803 corresponds to Humira (adalimumab), a biologic drug developed by AbbVie. It is indicated for multiple autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
Humira holds a dominant position in the biologics market for autoimmune diseases. As of 2022, it remains one of the top-selling drugs worldwide, with global sales exceeding $20 billion annually[1].
How does the competitive landscape impact Humira's market position?
Multiple biosimilars entered markets starting 2018, notably in Europe and later in the U.S. The U.S. biosimilar market gained traction after the expiration of certain patents in 2023, leading to increased competition.
Major biosimilars include:
- Amgen's Amjevita (adalimumab-atto)
- Samsung Bioepis's Hadlima (adalimumab-bwwd)
- Boehringer Ingelheim's Cyltezo (adalimumab-adbm)
Despite biosimilar entry, Humira maintains a significant market share through legal exclusivities and established physician prescribing habits.
What are the recent pricing trends?
Humira's list price in the U.S. was approximately $6,000 per month in 2022. Biosimilars retail around $3,000 to $4,000 per month, roughly 40-50% lower than the originator[2].
Pricing dynamics:
- Humira: Maintains the highest retail price among adalimumab formulations.
- Biosimilars: Prices exhibit a downward trend with increased market penetration, potentially reaching $2,500 or lower over the next 12-24 months.
Rebates and insurance negotiations further influence actual patient costs, often reducing co-pays significantly.
What are the projections for Humira's revenue and market share?
2023-2025 Market Outlook:
| Year |
Estimated Global Sales |
Competitive Share |
Notes |
| 2023 |
~$18-20 billion |
55-60% |
Biosimilar prevalence increasing, but Humira still dominant due to brand loyalty and legal exclusivities. |
| 2024 |
~$15-17 billion |
45-55% |
Biosimilar uptake accelerates; market share shifts accordingly. |
| 2025 |
~$12-14 billion |
35-45% |
Continued biosimilar disruption; patent litigations may impact availability. |
Analysts expect a gradual decline in Humira’s revenue due to biosimilar competition but project continued profitability for AbbVie through expanded indications and international sales.
How will regulatory and patent strategies influence future pricing?
AbbVie has implemented multiple patent defenses, including formulation patents and exclusivities in key regions, delaying biosimilar "authorized" competition.
In the U.S., patent litigation prolonged until late 2023. Recent settlements allowed biosimilar launches to proceed, which pressure pricing downward. Similar strategies in the EU extended monopolistic periods until 2025.
Legal defenses and patent thickets remain core tools, influencing market entry timelines and pricing erosion.
What are the implications for investors and stakeholders?
- For investors, Humira’s revenue streams will diminish over the next few years but remain substantial until patent protections lapse.
- For healthcare providers, biosimilars offer cost-saving alternatives, influencing prescribing patterns.
- For pharmaceutical companies, opportunities exist in biosimilar manufacturing, especially as patents expire.
What strategies could stabilize or grow market share post-patent expiry?
- Diversification into new indications.
- Expansion into emerging markets with slower biosimilar adoption.
- Clinical development of next-generation biosimilars with improved delivery or efficacy.
- Strategic litigation and patent filings to extend exclusivities.
Closing Summary
Humira (NDC 00143-9803) remains a top revenue-generating biologic despite biosimilar entry. Its pricing continues to decrease as biosimilars gain market share, with significant decline predicted over the next two years. Strategic patent defenses delay full biosimilar penetration, but overall market dynamics favor continued erosion of Humira’s dominance. Revenues are projected to decline, but the drug will remain profitable through international sales, new indications, and potential lifecycle management tactics.
Key Takeaways
- Humira's global sales exceeded $20 billion in 2022, with biosimilar competition intensifying post-2023 patent expiries.
- Biosimilars are priced 40-50% lower, with further reductions expected.
- Market share is expected to decline from over 55% in 2023 to below 40% by 2025.
- Patent litigation and legal strategies shape the timing of biosimilar market entry.
- Opportunities exist in emerging markets and through expanding indications.
FAQs
1. When did biosimilars for Humira enter the U.S. market?
Biosimilars launched in the U.S. starting 2023 following patent resolutions and legal settlements.
2. How much will biosimilars reduce treatment costs?
Biosimilar prices are roughly 40-50% lower than Humira’s list price, potentially decreasing costs to around $2,500/month.
3. Will Humira's revenue drop below $10 billion?
Likely not immediately; revenue is projected to decline to $12-$14 billion by 2025, stabilized by international markets and new approvals.
4. How long will Humira maintain profitability?
Through expanded indications and potential lifecycle management, profitability may persist until at least 2030.
5. What factors could accelerate Humira’s revenue decline?
Aggressive biosimilar pricing, market penetration strategies, patent invalidation, and competitor innovation.
References
[1] IQVIA. "Global Medicine Sales Data," 2022.
[2] EvaluatePharma. "Humira Biosimilar Pricing Trends," 2022.
